Q1 2022 Results slide image

Q1 2022 Results

Company overview Financial performance CRM Financial review Immunology Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology Immunology Appendix References Innovation: Clinical trials Abbreviations Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health 55 Investor Relations | Q1 2022 Results NOVARTIS | Reimagining Medicine
View entire presentation